Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Golvatinib |
Synonyms | |
Therapy Description |
Golvatinib (E7050) is a dual kinase inhibitor of c-Met (MET) and KDR (VEGFR2), which inhibits cell growth and proliferation (PMID: 25458359, PMID: 25278451). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Golvatinib | E7050|E-7050 | EPHB4 Inhibitor 6 MET Inhibitor 59 VEGFR2 Inhibitor 37 | Golvatinib (E7050) is a dual kinase inhibitor of c-Met (MET) and KDR (VEGFR2), which inhibits cell growth and proliferation (PMID: 25458359, PMID: 25278451). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01433991 | Phase Ib/II | Golvatinib Lenvatinib | E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) | Terminated | USA | 0 |